A biosimilar medicine is a highly similar version of an original brand of medicine. Introduction into the market provides competition and can trigger price reductions to the PBS through a process called Price Disclosure.
This means the Government can re-invest savings into other new treatments and health care services – like childcare, eldercare, mental health services, research and more.
Contact the GBMA to learn more about how biosimilar medicines can contribute to the future sustainability of the Australian healthcare system.
